Zydus Cadila has got the tentative approval from the US health regulator for marketing anti-diabetic sitagliptin and metformin hydrochloride in the US market.

Cadila Healthcare has said in a BSE filing that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market sitagliptin and metformin hydrochloride in the strength of 50mg/500 mg and 50mg/1000 mg.

It further said that the group has now nearly 120 approvals from the USFDA and so far filed 300 abbreviated new drug applications (ANDAs).

Read EquityPandit’s Technical Analysis on Nifty Pharma